(Q36130137)

12 August 2017

1 reference

title

Treatment of metastatic uveal melanoma: review and recommendations (English)

1 reference

12 August 2017

1 reference

D. M. Albert

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1589858

12 October 2022

A. S. Niffenegger

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1589858

12 October 2022

J. K. Willson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1589858

12 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1589858

12 October 2022

publication date

1 May 1992

1 reference

12 August 2017

published in

Survey of Ophthalmology

1 reference

12 August 2017

volume

36

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

429-438

1 reference

Resection of hepatic metastases from colorectal cancer

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Prognosis in uveal melanoma with extrascleral extension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Prognosis in metastatic choroidal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Excision of melanoma metastases to lung: problems in diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Metastatic choroidal melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Results with methyl-CCNU and DTIC in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

METASTATIC MELANOMA. A CLINICOPATHOLOGICAL STUDY.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Metastatic patterns of choroidal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Tumor-associated antibodies in the serum of patients with ocular melanoma. III. Immunoperoxidase detection

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Survival of patients with metastases from uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Taxol: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943--1952.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Mlalignant melanomas of the human uvea. Recent follow-up of cases in Denmark, 1943-1952.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Adjuvant Therapy for Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Prognosis in malignant melanoma of the skin. Significance of stage of disease, anatomical site, sex, age and period of diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Prognostic factors in small malignant melanomas of choroid and ciliary body

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Survival in metastatic ocular melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Adjuvant chemotherapy in ocular malignant melanoma. Study of 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Prognostic factors in choroidal and ciliary body melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Current approaches to the diagnosis and management of choroidal melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Disseminated melanoma. Biologic behavior and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

The incidence of metastases from untreated ciliary body and choroidal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

Results of operative treatment of intracranial metastatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2805%2980024-4

7 January 2021

10.1016/S0039-6257(05)80024-4

Identifiers

DOI

1 reference

12 August 2017

1 reference